BioSpace News Archive

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022.

Additional details are available in the Loan Agreement which is available under the Corporation’s SEDAR profile at www.sedar.com.

The Company will be presenting new data on plasma metabolic biomarkers for early cancer detection arising from its collaborative research and development works performed with Quebec-based Phytronix Technologies Inc.

CareDx, Inc. announced Reg Seeto’s selection by the newly formed International Society for Heart and Lung Transplantation Foundation to serve as Corporate Chair of the organization’s Global Steering Committee.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes.

Tempest Therapeutics, Inc. announced that two abstracts were accepted for presentation at the 2022 American Society of Clinical Oncology Annual Meeting taking place June 3-7, 2022 at the McCormick Place Convention Center in Chicago, IL.

Cullinan Oncology, Inc. announced the presentation of updated clinical research highlighting the therapeutic potential of its lead asset, CLN-081, in patients with epidermal growth factor receptor exon 20 insertion mutation positive non-small cell lung cancer at the 2022 American Society of Clinical Oncology Annual Meeting taking place in Chicago from June 3-7, 2022.

Karyopharm Therapeutics Inc. announced that four abstracts highlighting selinexor clinical research have been selected for presentation, including one oral presentation, at the upcoming 2022 American Society of Clinical Oncology Annual Meeting taking place June 3-7, 2022, in Chicago.

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that it will present a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that a poster describing the design of the Phase 1/2 trial of AU-007 will be presented during a Trials in Progress session at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.